FDA Clears Heartflow Coronary Plaque Technology

By Nicholas G. Miller


The Food and Drug Administration cleared Heartflow's technology to quantify coronary plaque and the platform is now available, the company said.

The technology, which uses AI and data from 273,000 patients, offers medical providers a visual representation of plaque types, allowing for rapid assessment of coronary artery disease location and severity.

Heartflow also said insurance provider Cigna would add the plaque analysis to its nationwide coverage, effective in October. UnitedHealth previously decided to cover Heartflow's plaque analysis.


Write to Nicholas G. Miller at nicholas.miller@wsj.com.


(END) Dow Jones Newswires

September 22, 2025 16:41 ET (20:41 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center